{"id":105,"date":"2026-02-12T12:53:35","date_gmt":"2026-02-12T11:53:35","guid":{"rendered":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/?page_id=105"},"modified":"2026-09-28T17:04:29","modified_gmt":"2026-09-28T15:04:29","slug":"friday-october-2","status":"publish","type":"page","link":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/program\/friday-october-2\/","title":{"rendered":"Friday, October 2nd"},"content":{"rendered":"
\r\n \r\n\t
\r\n\t\t
\r\n\t\t\t09:00 – 10:15<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tSESSION 8<\/strong> AML combination therapies: total oral therapies and triplets on the horizon<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t
\r\n\t\t
Chairs:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. Alessandro Isidori,<\/p>\r\n\t\t\t\t

Marche Nord Hospital. Pesaro, Italy<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Carlos Plaza,<\/p>\r\n\t\t\t\t

UEES Clinic y SOLCA. Guayaquil, Ecuador<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Claudia N\u00fa\u00f1ez-Torr\u00f3n,<\/p>\r\n\t\t\t\t

Hospital Universitario Infanta Sof\u00eda. Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
09:00 – 09:20<\/div>\r\n\t\t
\r\n\t\t\t

Moving toward total oral therapy<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Gabriela Rodr\u00edguez Mac\u00edas,<\/p>\r\n\t\t\t\t

Hospital General Universitario Gregorio Mara\u00f1\u00f3n. Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
09:20 – 09:40<\/div>\r\n\t\t
\r\n\t\t\t

Triplets: is this really low-intensity? Venetoclax-based therapies in the U.S.<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Naval Daver,<\/p>\r\n\t\t\t\t

MD Anderson Cancer Center. Houston, USA<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
09:40 – 10:00<\/div>\r\n\t\t
\r\n\t\t\t

New therapeutic combinations in AML: moving beyond intensive chemotherapy<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Hartmut D\u00f6hner,<\/p>\r\n\t\t\t\t

Universit\u00e4tsklinikum, Ulm. Ulm, Germany<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
10:00 – 10:15<\/div>\r\n\t\t
\r\n\t\t\t

Discussion<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
10:15 – 10:40<\/div>\r\n\t\t
\r\n\t\t\t

Coffee break<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
\r\n\t\t\t10:40 – 11:20<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tSESSION 9<\/strong> Colloquium<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n\t
\r\n\t\t
10:40 – 11:05<\/div>\r\n\t\t
\r\n\t\t\t

Daily challenges and complex decisions 2. FLT3 AML<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Josefina Serrano,<\/p>\r\n\t\t\t\t

Hospital Universitario Reina Sof\u00eda de C\u00f3rdoba, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Mar Tormo,<\/p>\r\n\t\t\t\t

Hospital Cl\u00ednico Universitario de Valencia, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Adolfo de la Fuente,<\/p>\r\n\t\t\t\t

MD Anderson Cancer Center Madrid-Hospiten, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n\t

\r\n\t\t
11:05 – 11:20<\/div>\r\n\t\t
\r\n\t\t\t

Discussion<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
\r\n\t\t\t11:20 – 12:40<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tSESSION 10<\/strong> Limphoblastic Leukemia<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t
\r\n\t\t
Chairs:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. Gilberto Barranco,<\/p>\r\n\t\t\t\t

Hospital General de M\u00e9xico, Mexico City<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Virginia Abello,<\/p>\r\n\t\t\t\t

Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center. Bogot\u00e1, Colombia<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Mayte Olave,<\/p>\r\n\t\t\t\t

Hospital Cl\u00ednico Universitario Lozano Blesa. Zaragoza, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
11:20 – 11:40<\/div>\r\n\t\t
\r\n\t\t\t

Decisions based on MRD in ALL<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Elias Jabbour,<\/p>\r\n\t\t\t\t

MD Anderson Cancer Center. Houston, USA<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
11:40 – 12:25<\/div>\r\n\t\t
\r\n\t\t\t

ALL colloquium <\/strong>
\r\n\t\t\t\tFirst-line treatment for B-ALL in adults: practical tips for day-to-day management<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Mar\u00eda Calbacho,<\/p>\r\n\t\t\t\t

Hospital Universitario 12 de Octubre. Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. M\u00f3nica Cabrero,<\/p>\r\n\t\t\t\t

Hospital Cl\u00ednico Universitario de Salamanca, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
12:25 – 12:40<\/div>\r\n\t\t
\r\n\t\t\t

Discussion<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
\r\n\t\t\t12:40 – 13:40<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tSESSION 11<\/strong> Augemented intelligence workshop<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t
\r\n\t\t
Chairs:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. Carlos Jim\u00e9nez-Chill\u00f3n,<\/p>\r\n\t\t\t\t

Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Joaqu\u00edn S\u00e1nchez,<\/p>\r\n\t\t\t\t

Hospital Universitario Reina Sof\u00eda. C\u00f3rdoba, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Adolfo de la Fuente,<\/p>\r\n\t\t\t\t

MD Anderson Cancer Center Madrid-Hospiten, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
Experts:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Miguel \u00c1ngel Sierra,<\/p>\r\n\t\t\t\t

Account Manager – Healthcare & Life Science, Google<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

C\u00e9sar Tapias,<\/p>\r\n\t\t\t\t

Data & AI Sales for Health Media Travel & Public, Google<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
13:40 – 14:40<\/div>\r\n\t\t
\r\n\t\t\t

Lunch<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n<\/div>\r\n \r\n

\r\n \r\n\t
\r\n\t\t
\r\n\t\t\t14:40 – 16:05<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tSESSION 12<\/strong> AML-4 Post-Remision strategies to prevent relapse<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t
\r\n\t\t
Chairs:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. Joana Brioso Infante,<\/p>\r\n\t\t\t\t

Centro Hospitalar Universit\u00e1rio de Lisboa Norte, Portugal<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. M\u00f3nica Alejandra Romero,<\/p>\r\n\t\t\t\t

Hospital Cl\u00ednico Regional Dr. Guillermo Grant Benavente. Concepci\u00f3n, Chile<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Mika Kontro,<\/p>\r\n\t\t\t\t

University of Helsinki, Finland<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
14:40 – 15:00<\/div>\r\n\t\t
\r\n\t\t\t

Impact of the redefinition of the MRD (ELN 2025)<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Eva Barrag\u00e1n,<\/p>\r\n\t\t\t\t

Hospital Universitario y Polit\u00e9cnico La Fe. Valencia, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
15:00 – 15:45<\/div>\r\n\t\t
\r\n\t\t\t

Colloquium: MRD in AML from prognostic factor to actionable target<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Adolfo de la Fuente,<\/p>\r\n\t\t\t\t

MD Anderson Cancer Center Madrid-Hospiten, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Joaqu\u00edn S\u00e1nchez,<\/p>\r\n\t\t\t\t

Hospital Universitario Reina Sof\u00eda. C\u00f3rdoba, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Jordi Esteve,<\/p>\r\n\t\t\t\t

Hospital Clinic de Barcelona, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Hartmut D\u00f6hner,<\/p>\r\n\t\t\t\t

Universit\u00e4tsklinikum Ulm, Germany<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
15:45 – 16:05<\/div>\r\n\t\t
\r\n\t\t\t

Discussion<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
16:05 – 16:25<\/div>\r\n\t\t
\r\n\t\t\t

Coffee break<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
\r\n\t\t\t16:25 – 17:40<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tSESSION 13<\/strong> AML-5 menin inhibitors<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t
\r\n\t\t
Chairs:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. Mika Kontro,<\/p>\r\n\t\t\t\t

University of Helsinki, Finland<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Anne Louise T\u00f8lb\u00f8ll S\u00f8rensen,<\/p>\r\n\t\t\t\t

Rigshospitalet Copenhagen University, Denmark<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Jordi Esteve,<\/p>\r\n\t\t\t\t

Hospital Clinic Barcelona, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
16:25 – 16:45<\/div>\r\n\t\t
\r\n\t\t\t

AML NPM1 and ALM KMT2A rearrangement: biological basis, oncogenic potential, and mechanisms of resistance<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Joaqu\u00edn S\u00e1nchez,<\/p>\r\n\t\t\t\t

Hospital Universitario Reina Sof\u00eda. C\u00f3rdoba, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
16:45 – 17:05<\/div>\r\n\t\t
\r\n\t\t\t

Menin inhibitors in KMT2A-rearranged, NPM1-mutated, and other HOX-expressing leukemias<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Issa Ghayas,<\/p>\r\n\t\t\t\t

MD Anderson Cancer Center. Houston, USA<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
17:05 – 17:25<\/div>\r\n\t\t
\r\n\t\t\t

Menin inhibitors as monotherapy: from clinical trials to real-world practice<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Cristina Papayannidis,<\/p>\r\n\t\t\t\t

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
17:25 – 17:40<\/div>\r\n\t\t
\r\n\t\t\t

Discussion<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
\r\n\t\t\t17:40 – 18:40<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tSESSION 14<\/strong> AML-6 FLT3-mutated AML<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t
\r\n\t\t
Chairs:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. Isolda Fern\u00e1ndez,<\/p>\r\n\t\t\t\t

Centro de Hematolog\u00eda Pavlovsky. Buenos Aires, Argentina<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Claudia Sossa,<\/p>\r\n\t\t\t\t

Complejo M\u00e9dico Fundaci\u00f3n Oftalmol\u00f3gica de Santander – Cl\u00ednica Carlos Ardila Lulle (FOSCAL). Bucaramanga, Colombia<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
17:40 – 18:20<\/div>\r\n\t\t
\r\n\t\t\t

Colloquium<\/strong>
FLT3-mutated AML (low-intensity treatment vs. intensive chemotherapy, transplant for all?)<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Jordi Esteve,<\/p>\r\n\t\t\t\t

Hospital Clinic Barcelona, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Alessandro Isidori,<\/p>\r\n\t\t\t\t

Marche Nord Hospital. Pesaro, Italy<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Naval Daver,<\/p>\r\n\t\t\t\t

MD Anderson Cancer Center. Houston, USA<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
18:20 – 18:40<\/div>\r\n\t\t
\r\n\t\t\t

Discussion<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
18:40 – 18:50<\/div>\r\n\t\t
\r\n\t\t\t

Closing and farewell<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n<\/div>","protected":false},"excerpt":{"rendered":"09:00 – 10:15 SESSION 8 AML combination therapies: total oral therapies and triplets on the horizon Chairs: Dr. Alessandro Isidori, Marche Nord Hospital. Pesaro, Italy Dr. Carlos Plaza, UEES Clinic y SOLCA. Guayaquil, Ecuador Dr. Claudia N\u00fa\u00f1ez-Torr\u00f3n, Hospital Universitario Infanta Sof\u00eda. Madrid, Spain 09:00 – 09:20 Moving toward total oral therapy Dr. Gabriela Rodr\u00edguez Mac\u00edas, … Leer m\u00e1s<\/a>","protected":false},"author":2,"featured_media":0,"parent":45,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"template-internas.php","meta":{"footnotes":""},"class_list":["post-105","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/pages\/105","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/comments?post=105"}],"version-history":[{"count":18,"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/pages\/105\/revisions"}],"predecessor-version":[{"id":255,"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/pages\/105\/revisions\/255"}],"up":[{"embeddable":true,"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/pages\/45"}],"wp:attachment":[{"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/media?parent=105"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}